The peer-reviewed publication strengthens Annamycin's differentiation as a potentially safer anthracycline, which could support regulatory discussions and physician adoption if approved. Monitor for updates from the ongoing MIRACLE Phase 2/3 trial (MB-108) in R/R AML, as efficacy data will be the next major catalyst.
Price Chart
Executive Summary
Moleculin Biotech announced the publication of a peer-reviewed pooled analysis of Annamycin's cardiac safety in Frontiers in Cardiovascular Medicine. The analysis of 90 patients across five clinical trials found no clinical or subclinical evidence of cardiotoxicity, even at cumulative doses exceeding traditional anthracycline limits, with independent evaluation by Cleveland Clinic. This is a positive de-risking data point for Annamycin's safety profile but does not change the near-term regulatory or financial outlook.
Key Facts
- Publication in Frontiers in Cardiovascular Medicine of a pooled cardiac safety analysis of Annamycin across five clinical trials.
- Analysis included 90 patients (78 with paired echocardiographic data) in AML and metastatic STS.
- Mean LVEF unchanged: 60.6% at baseline vs 60.0% post-treatment (p=0.84).
- No relationship between cumulative Annamycin dose and LVEF change, and no treatment-related cardiotoxicity detected via ECG, troponin, or global longitudinal strain.
- Median cumulative Annamycin dose was 660 mg/m², exceeding conventional anthracycline lifetime limits.
- Independent evaluation by Cleveland Clinic cardio-oncology laboratory confirmed findings.
Financial Impact
No financial figures provided in the filing; this is a clinical data disclosure with no revenue or guidance impact.
Risk Factors
- The analysis is retrospective/pooled, not a prospective randomized trial — selection bias cannot be ruled out.
- No efficacy data in this filing; cardiac safety alone does not guarantee clinical or commercial success.
- Moleculin requires additional financing to complete its pivotal trial, as stated in the forward-looking statements.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-031280 |
| Exhibit: ex_1019749.htm | 0001437749-26-031280 |
| Document: 0001437749-26-031280-index-headers.html | 0001437749-26-031280 |
| Document: 0001437749-26-031280-index.html | 0001437749-26-031280 |
| Document: 0001437749-26-031280.txt | 0001437749-26-031280 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $6.19 | awaiting T+20 | — | $7.09 (+14.46%) |
Oct 16, 2026 10d ago | 8-K | $0.2804 | awaiting T+20 | — | $7.09 (+2426.75%) |
Oct 9, 2026 16d ago | 8-K | $0.4139 | awaiting T+20 | — | $7.09 (+1611.77%) |
Oct 5, 2026 21d ago | 8-K | $0.4766 | awaiting T+20 | — | $7.09 (+1386.57%) |
Sep 29, 2026 27d ago | 8-K | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 29, 2026 27d ago | Press Release | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 28, 2026 28d ago | 8-K | $0.5690 | awaiting T+20 | — | $7.09 (+1145.17%) |
Sep 25, 2026 4w ago | 8-K | $0.6016 $6.50 | ▲ +980.45% | ▲ +981.93% | $7.09 (+1077.69%) |
Sep 23, 2026 4w ago | 8-K | $0.5279 $6.31 | ▲ +1095.30% | ▲ +1094.61% | $7.09 (+1242.11%) |
Sep 18, 2026 5w ago | 8-K | $0.5202 | awaiting T+20 | — | $7.09 (−1261.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers